On June 15, 2021, RAMM Pharma Corp., a leader in plant-derived cannabinoid pharmaceutical and other cannabis-based products, completed its acquisition of Canapar Corp. Pursuant to the terms of the acquisition, RAMM acquired of all the common shares of Canapar that RAMM did not previously own (including shares of Canapar issuable upon the conversion of outstanding promissory notes) in exchange for an aggregate of 21,778,752 common shares of RAMM at a deemed value of $1.20 per share of RAMM for a total purchase price of approximately $26.1 million.
Cassels acted for RAMM.